

LivaNova

Health innovation that matters


LivaNova Investor Day

Strategy

Damien McDonald

Chief Executive Officer

September 14, 2017



Safe Harbor Statement

Certain statements in this presentation, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, our actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties and other important factors, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking statements contained in this press release, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-4 and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova.

The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this presentation to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this presentation.

We are a \$1.2B focused medical innovator


Improving quality of patients' lives

Strong leadership position in Neuromodulation and Cardiac Surgery

Targeting underserved and high-growth market segments



Leading positions in critical areas of treatment



Exploring strategic options for Cardiac Rhythm Management

Sharpening our focus on areas of strength and market leadership

Committed to ensuring portfolio is optimally positioned to deliver long-term value

CRM is no longer a fit within LivaNova's portfolio, but is a global business with attractive assets, a robust pipeline and growth potential

No timeline for completion of the process has been set

Do not intend to disclose further developments until a definitive decision has been reached



Committed to ensuring portfolio is optimally positioned to deliver long-term value

Leading positions in Neuromodulation and Cardiac Surgery

Innovative technology focusing on high-margin products

Targeting high-growth and underserved markets

Executing disciplined portfolio management to strengthen and enhance category leadership

New management team has strategy to deliver enhanced shareholder value

LivaNova:
An attractive
long-term
investment

Focusing portfolio on “Head & Heart”

	NEUROMODULATION	CARDIAC SURGERY	
		CARDIOPULMONARY	HEART VALVES
	Creator, leader of VNS Therapy	Market-leading positions	Only sutureless valve on the market
Global Market (2016)*	\$4.1B	\$2.0B	\$1.7B
Market Growth	Low-double-digit	Low-single-digit	Low-single-digit
Sales (2016)*	\$350M	\$475M	\$140M
Disease State	Drug-resistant epilepsy Treatment-resistant depression (TRD)	Heart valve disease Coronary disease Congenital heart defect Heart failure	
Customers	Neurologists Epileptologists Psychiatrists Neurosurgeons Patients	Perfusionists Cardiac Surgeons Cardiologists	

Our portfolio has multiple near-term growth drivers

NEUROMODULATION

AspireSR® advances the science of VNS Therapy®



100,000 patients treated with VNS Therapy

CARDIAC SURGERY

S5® HLM reduces transfusions and improves recovery



40 years as market leader in heart-lung machines

Inspire® oxygenator provides personalized perfusion



750,000+ patients treated with Inspire

Perceval® optimizes the surgical approach to sutureless aortic valve replacement



10 years of clinical use

Our portfolio has multiple mid- to long-term growth drivers: strategic portfolio initiatives

TREATMENT-RESISTANT DEPRESSION

VNS Therapy may provide better outcomes and symptom improvement



Depression is the leading cause of disability worldwide

TRANSCATHETER MITRAL VALVE REPLACEMENT

Unique transeptal investigational device



2-3 times the size of aortic market opportunity


CHRONIC HEART FAILURE

Novel delivery of Autonomic Regulation Therapy (ART) may improve regulation of cardiovascular function




Leading cause of morbidity and mortality

M&A strategy targets growth and margin expansion



Clear roadmap for value creation



Four pillars to transform the organization



Strategy to accelerate growth

Drive demand

Build pipeline



Expand portfolio

LivaNova
Sales Force Effectiveness
KPIs


TARGET TO IMPROVE
Set targets in order of priority according to top level PD matrix

Owner	YTD	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC		
Level 1 KPIs															
CP - ratio (low - 1 / rep / quarter)	John Brown	0.0	Plan	No historical data - will start tracking in July							0.0	0.0	0.0	0.0	0.0
		0.0	Act												
		0.0	PV												
		0%	Plan	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	Act	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	Var	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	PV												
AV - % of Target accounts implanted (Have implanted regularly in last 2 months)	Jane Smith	0.0	Plan	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0.0	Act	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0.0	Var	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0%	Plan	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	Act	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	Var	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	PV												
AV - Personal Average Daily Sales Units (ADU)	Chris Thomas	0.0	Plan	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0.0	Act	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0.0	Var	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0%	Plan	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	Act	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	Var	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	PV												
NM - # new implants / rep / week	Maria Lurie	0.0	Plan	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0.0	Act	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0.0	Var	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0%	Plan	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	Act	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	Var	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	PV												
CRM - Active implants / rep / mo	Joe Johnson	0.0	Plan	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0.0	Act	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0.0	Var	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0%	Plan	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	Act	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	Var	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	PV												
CRM - % main body revenue mix @ 70%	Joe Johnson	0.0	Plan	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0.0	Act	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0.0	Var	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%		
		0%	PV												
Level 2 KPIs															
# open territories	Frank Letter	0.0	Plan	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0.0	Act	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		
		0.0	Var	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		

of positions that...
of reqs...
of...


Significant opportunities to improve profitability



Attracting new talent and developing existing talent



Integrated Talent Strategy




Creating a culture of continuous improvement

Discipline

Accountability

Teamwork



Our size allows us to make decisions and implement change swiftly

We are blending discipline and accountability with an innovative spirit

We have a global and diverse workforce

Our mission is to improve patients' lives

We are a compelling investment

Leadership positions in most of our served markets

Innovative products with patient/physician benefits

Significant barriers to entry

Opportunities for geographical expansion

Multiple drivers to accelerate growth

Executing on initiatives for margin expansion

We are poised for success

Growing	Top and bottom line	<ul style="list-style-type: none">• Large, globally expanding markets• Broad geographic presence• Growing positions in head and heart• Customer-centric innovation• Realizing capital and operational efficiencies
Transforming	Organization	<ul style="list-style-type: none">• Four pillars transforming organization• Growth, profitability, talent, culture
Creating	Value	<ul style="list-style-type: none">• Clear roadmap for value creation• Invest and grow• Accelerate growth• Positioned for success

LivaNova

Health innovation that matters